Providing compassionate access for public patients with inoperable advanced or recurrent pancreatic cancer, this program is a first-of-its-kind collaboration between GenesisCare Foundation, GenesisCare UK, the Pancreatic Cancer Research Fund, the University of Oxford and ViewRay.
GenesisCare Foundation’s Pancreatic Compassionate Access Program allows patients to be treated using stereotactic ablative radiotherapy (SABR) with the UK’s first MRIdian machine, providing live, detailed images and increased accuracy in targeting the tumour and avoiding major organs situated nearby.1
The program is also generating patient outcome data that will help embed this technology into oncology practice.